Lung Cancer Trials Ask AI to find trials
Active Not RecruitingPhase 1NCT06116786
Official study title

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Study summary

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedJNJ-86974680 and Cetrelimab

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 25, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1

Interventional

Where is it offered?15 U.S. locations

Locations may change over time.

Who runs it?Johnson & Johnson Enterprise Innovation Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Johnson & Johnson Enterprise Innovation Inc.
Interventions being studied
Drug: JNJ-86974680; Drug: Cetrelimab; Radiation: Radiation Therapy
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
  • Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase \[ALK\], c-ros oncogene 1 \[ROS1\], v-raf murine sarcoma viral oncogene homolog B1 \[BRAF\]) must have received all approved targeted therapies and have progressed
  • Part 2: No targetable mutations (for example, EGFR \[epidermal growth factor receptor\], ALK \[anaplastic lymphoma kinase\], ROS1\[c-ros oncogene 1\], and BRAF \[B-Raf proto-oncogene, serine/threonine kinase\])
  • Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy
  • For Cohort B of Part 2: Previously treated with anti-PD-1/PD-L1 therapy for metastatic disease as the prior line of therapy
  • For Cohort C of Part 2: Treatment naïve
  • Adequate organ function
Reasons someone may not be able to joinExclusion criteria
  • Active central nervous system (CNS) disease involvement
  • Active autoimmune disease
  • Active infection
  • History of solid organ or hematologic stem cell transplantation

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • City of Hope 1Newnan, Georgia
  • Hackensack University Medical CenterHackensack, New Jersey
  • Roswell Park Comprehensive Cancer CenterBuffalo, New York
  • Herbert Irving Comprehensive Cancer Center Columbia University Medical CenterNew York, New York
  • Providence Portland Medical CenterPortland, Oregon
  • Thomas Jefferson UniversityPhiladelphia, Pennsylvania
  • Next VirginiaFairfax, Virginia
  • Charite Research Organisation GmbHBerlin
  • Universitaetsklinikum Giessen und Marburg GmbHGiessen
  • Severance Hospital Yonsei University Health SystemSeoul
  • Samsung Medical CenterSeoul
  • Hosp. Univ. Quiron DexeusBarcelona

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 25, 2026. Always confirm current availability with the study team.

View original record ↗